Odisha News In English

Prameya English, Prameyanews.com, Odisha Latest News, Odisha News Online

previous arrow
next arrow

DCGI gives permission to BharatBiotech for intranasal booster dose trials

28/01/2022 at 2:18 PM

New Delhi, Jan 28: The Drugs Controller General of India (DCGI) on Friday granted permission to BharatBiotech for intranasal booster dose trials.

The BharatBiotech has proposed the booster dose for those who have been already been innoculated against Covid with Covishield and Covaxin vaccines.

It aims to conduct clinical trials on 5,000 subjects – 50 per cent vaccinated with Covishield and 50 per cent vaccinated with Covaxin.

The interval between the second dose and booster dose will be six months, sources said.

The company had sought permission to conduct clinical trials for its intranasal booster dose in December last year.

   Related Posts